Citation:Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, et al 2014

From Cancer Guidelines Wiki

Citation


Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, et al. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol 2014 Jun 20;32(18):1902-8 Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/24841974.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
What is the optimal third-line therapy in unselected patients with stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted

Compare quality appraisals for each clinical question

Cited by

  1. What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?
  2. What is the optimal third-line therapy in unselected patients with stage IV inoperable NSCLC?